FBDD Fragments Base Drugs Discovery | Design
   
               
Search    
18-Jul-2014
  IOTA publishes review with Genentech scientists describing the use of mechanism-informed phenotypic screening (MIPS) in oncology drug discovery
   
2-Apr-2014
  IOTA Pharmaceuticals in 7.8M consortium tackling neglected parasitic diseases
   
21-Sep-2012
  IOTA InFarmatik Press Release
   
22-Feb-2011
  IOTA announces KINOMED, a new partnership to accelerate protein kinase drug discovery Cambridge, UK / Odense, Denmark / Lund, Sweden, February 22, 2011
   
17-Aug-2009
  New consortium to develop drugs for neglected tropical diseases
   
23-Apr-2008
  IOTA announces SPR initiative with Beactica AB
   
21-Dec-2007
  IOTA announces FBDD screening services
   
21-Dec-2007
  IOTA announces collaboration with Vitas M-laboratory and new FBDD library:IOTA-Vitas 4000
   
5-Aug-2007
  IOTA Pharmaceuticals established; research centers in the UK, the Netherlands, and India.
   
3-Aug-2007
  IOTA announces FBDD Initiative with the VU University, Amsterdam
   
25-Sep-2007
  IOTA announces first FBDD product: IOTA Diverse 1500
   
 
 
IOTA has a close working relationship with the Department of Medicinal Chemistry at the Free University of Amsterdam.
 
Built on drug discovery expertise in the field of pharmacological targets such as the histamine, acetylcholine, chemokine and nuclear hormone receptors, and led by IOTA co-founder Dr Iwan de Esch, the VU Discovery team has extensive experience working in drug discovery projects alongside both international pharma and academic partners.
 
VU Discovery Studies
Histamine Receptors Nicotinic AChR / AChBPs
Kinases Nuclear Hormone Receptors
Chemokine Receptors  
Copyright 2007 IOTA Pharmaceuticals  |   Site by Dots & Coms